Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

199.54
-4.1800-2.05%
Post-market: 200.901.36+0.68%19:59 EST
Volume:2.59M
Turnover:523.80M
Market Cap:10.62B
PE:31.61
High:205.99
Open:203.93
Low:199.26
Close:203.72
52wk High:222.29
52wk Low:159.68
Shares:53.20M
Float Shares:53.20M
Volume Ratio:1.40
T/O Rate:4.87%
Dividend:0.35
Dividend Rate:0.17%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.30
PE(LYR):5.65

Loading ...

Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says

MT Newswires Live
·
Nov 20

Tentarix Targets Completion of AbbVie, Gilead Partnered Programs Within 12 Months

Reuters
·
Nov 19

Gilead Sciences (GILD) Has Investors Looking Closer, What Is Behind The Attention?

Simply Wall St.
·
Nov 19

Adagene Doses First Patient in Phase 1 Study of ADG138

TIPRANKS
·
Nov 19

Chemomab Reports Q3 Results as SEC Declares Merger Registration Effective

TIPRANKS
·
Nov 19

Sector Update: Health Care Stocks Lower Pre-Bell Thursday

MT Newswires Live
·
Nov 19

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Anthropic Stock Market Debut

MT Newswires Live
·
Nov 19

Goldman Sachs Adjusts Regeneron Pharmaceuticals PT to $1,115 From $1,110

MT Newswires Live
·
Nov 19

Regeneron to Present Ordspono Trial Results in Relapsed or Refractory Marginal Zone Lymphoma at ASH

Reuters
·
Nov 19

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

GlobeNewswire
·
Nov 19

Argenica Reports Xaranetide Phase 2 Stroke Trial Results

TIPRANKS
·
Nov 19

FDA Maintains Hold on Xaranetide Stroke Trial

TIPRANKS
·
Nov 19

FDA Approval Could Be A Big Moment For Regeneron Stock (REGN)

Simply Wall St.
·
Nov 19

Amgen Inc : Piper Sandler Raises Target Price to $542 from $457

THOMSON REUTERS
·
Nov 19

Regeneron Says Muscular Disorder Treatment Livsayis Gets FDA Approval

Dow Jones
·
Nov 19

FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis

Reuters
·
Nov 19

Livsayis™ (Cemdisiran) Approved by the FDA as First and Only Sirna Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

THOMSON REUTERS
·
Nov 19

Regeneron Pharmaceuticals - Livsayis Available Only Through Livsayis Rems Program

THOMSON REUTERS
·
Nov 19

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

GlobeNewswire
·
Nov 19

Lakefront Biotherapeutics Creates 150,000 Subscription Rights Plan

TIPRANKS
·
Nov 19